Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.53 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 6/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 5/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5424647 | 0.89 | HTR2A (0.62) | HTR2ATLR9DRD2DRD4DRD3 | |
| SCHEMBL5417422 | 0.88 | HTR2A (0.56) | HTR2ATLR9DRD2DRD4DRD3 | |
| SCHEMBL5415363 | 0.88 | HTR2A (0.53) | HTR2ADRD2DRD4DRD3HTR2C | |
| SCHEMBL5420662 | 0.87 | HTR2A (0.53) | HTR2ATLR9DRD2DRD4DRD3 | |
| SCHEMBL5431724 | 0.87 | HTR2A (0.56) | HTR2ATLR9DRD2DRD4DRD3 | |
| SCHEMBL4710595 | 0.83 | HTR2A (0.62) | HTR2ATLR9DRD2HTR2CKCNH2 | |
| SCHEMBL5427628 | 0.81 | MEN1 (0.59) | HTR2ADRD2DRD4DRD3HTR2C | |
| SCHEMBL5425718 | 0.81 | HTR2A (0.59) | HTR2ATLR9DRD2DRD4DRD3 | |
| SCHEMBL5425794 | 0.81 | HTR2A (0.56) | HTR2ADRD2DRD3HTR2CKCNH2 | |
| SCHEMBL5419288 | 0.80 | HTR2A (0.53) | HTR2ATLR9DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197603-A1 | Substituted indole ligands for the orl-1 receptor | GLAXOSMITHKLINE S.P.A. (IT) | 2007-08-23 | — | — | US | claimed |
| US-20070197603-A1 | Substituted indole ligands for the orl-1 receptor | GLAXOSMITHKLINE S.P.A. (IT) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197603-A1 | Substituted indole ligands for the orl-1 receptor | OGFRL1, OPRL1, ORMDL3 | HTR2A 147/4885TLR9 715/4885DRD2 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.